Early clinical development of bevacizumab was focused on several solid tumor types associated with VEGF driven angiogenesis, including non-small-cell lung cancer (NSCLC) (Seto et al., 2006), metastatic colorectal cancer (CRC) (Des Guetz et al., 2006), metastatic breast cancer (BC) (Foekens et al., 2001), glioblastoma multiforme (GBM) (Flynn et al., 2008), and ovarian cancer (OC) (Choi et al., 2015). Here, VEGFA is linked to non-small cell lung carcinoma.